caa a22 4500 465789773 CHVBK 20180323112020.0 cr unu---uuuuu 170327e19900301xx s 000 0 eng 10.1007/BF00171992 doi (NATIONALLICENCE)springer-10.1007/BF00171992 A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy [Elektronische Daten] An Eastern Cooperative Oncology group pilot study [Donald Trump, John Marsh, Larry Kvols, Dennis Citrin, Thomas Davis, Richard Hahn, Steven Vogl] Summary: Twenty-nine patients with metastatic prostate cancer progressing after hormonal therapy (orchiectomy 19, diethylstilbesterol 10) and who had never received cytotoxic therapy were treated with carboplatin. Patients had good clinical performance status (66% PS 0,1) and adequate renal (creatinine < 2.0 mg/dL) and bone marrow function. The standard dose of carboplatin administered was 400 mg/sq m. Seventeen patients received this dose and 12 either 320 mg/sq m or 250 mg/sq m based on reduced renal function or prior radiation. Five patients had bidimensionally measurable disease: one experienced a partial regression of cervical lymph node metastases of 97 days duration. Twenty-four patients had metastatic disease evaluable by clinical status, bone scan and acid phosphatase. In one patient > 50% reduction in number of abnormal areas of bone scan uptake occurred; 3 patients experienced improvement in clinical status; in no patient did an elevated prostate acid phosphatase return to normal. All patients entered on study have progressed and died: median time to progression was 94 days (6 to 625 days); median survival was 297 days (6-1152 days). The primary toxicity of carboplatin was myelosuppression. The median WBC and platelet nadirs after cycle one were 3150/cu mm and 93,000/cu mm, respectively. Dose escalations to grade 2 or greater myelosuppression were mandated. Twenty-six achieved at least grade 2 myelosuppression during carboplatin treatment. We conclude that carboplatin administered at this dose and schedule has no important activity in hormone refractory prostate cancer. Kluwer Academic Publishers, 1990 prostate cancer nationallicence carboplatin nationallicence Trump Donald University of Wisconsin Clinical Cancer Center, 21076, Madison WI, CA, USA aut Marsh John Yale School of Medicine, 15485, New Haven, CT, CA, USA aut Kvols Larry Mayo Clinic, 13650, Rochester, MN, CA, USA aut Citrin Dennis Northwestern University Medical Center, 14958, Chicago, IL, CA, USA aut Davis Thomas University of Wisconsin Clinical Cancer Center, 21076, Madison WI, CA, USA aut Hahn Richard Mayo Clinic, 13650, Rochester, MN, CA, USA aut Vogl Steven Albert Einstein College of Medicine, 14958, Bronx, NY, CA, USA aut Investigational New Drugs Kluwer Academic Publishers 8(1990-03-01), S91-S94 0167-6997 8<S91 1990 8 10637 https://doi.org/10.1007/BF00171992 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00171992 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Trump Donald University of Wisconsin Clinical Cancer Center, 21076, Madison WI, CA, USA aut NATIONALLICENCE 700 1- Marsh John Yale School of Medicine, 15485, New Haven, CT, CA, USA aut NATIONALLICENCE 700 1- Kvols Larry Mayo Clinic, 13650, Rochester, MN, CA, USA aut NATIONALLICENCE 700 1- Citrin Dennis Northwestern University Medical Center, 14958, Chicago, IL, CA, USA aut NATIONALLICENCE 700 1- Davis Thomas University of Wisconsin Clinical Cancer Center, 21076, Madison WI, CA, USA aut NATIONALLICENCE 700 1- Hahn Richard Mayo Clinic, 13650, Rochester, MN, CA, USA aut NATIONALLICENCE 700 1- Vogl Steven Albert Einstein College of Medicine, 14958, Bronx, NY, CA, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8(1990-03-01), S91-S94 0167-6997 8<S91 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer